Different mechanisms play a role in the anti‐tumour effect of mAbs and both target engagement with the Fab arm as well as Fc‐mediated effector functions contribute to the efficacy of treatment. As Ig isotypes differ in their ability to bind to FcRs on immune cells as well as in their ability to activate complement, they differ in the immune responses they activate. Therefore, the choice of antibody isotype for therapeutic mAbs is dictated by its intended mechanism of action. Here, we discuss the current knowledge of the therapeutic effector functions of different isotypes and Fc‐engineering strategies to improve mAbs application.

No abstract

No abstract

<p>Amino acid sequence of designed Thy1.1-MHC-1 construct</p>